The first randomized controlled trial (phase IIa) assessed the effect of a single intravenous infusion of the first anti-IL-5 monoclonal antibody [SB-240563] on the airway status after a challenge with an inhaled allergen in unselected patients with mild asthma conducted in 2000. This evidence concerns the gene IL5 and asthma.